Patent US2307561A successfully refreshed from Google Patents.
Patent US4714681A successfully refreshed from Google Patents.
US4714681A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Quadroma cells and trioma cells and methods for the production of same
Assignee: BOARD OF REAGENTS UNIVERSITY OF TEXAS SYSTEM CANCER CENTER
•
Filing: 1984-06-18
•
Granted: 1987-12-22
•
Expires: 2004-06-18
Abstract
Abstract Antibodies having binding affinity for two desired antigens, hereinafter "recombinant monoclonal antibodies"; recombinant monoclonal antibodies produced by a quadroma cell or a trioma cell; and methods for producing recombinant monoclonal antibodies by means of a quadroma cell or a trioma cell, wherein a quadroma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a hybridoma cell which produces an antibody having specific binding affinity for another desired antigen, and wherein a trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a lymphocyte which produces an antibody having specific binding affinity to another desired antigen.
Inventors
- 👤 Christopher L. Reading
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:38
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/577; C; C07; C07K; C07K16/00; C07K16/46; C07K16/468; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 60
Claim 1
Independent Claim
70 words
A quadroma cell, wherein said quadroma cell is the fusion product of a first hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen and a second hybridoma cell which produces an antibody having specific binding affinity for a second desired antigen, and wherein said quadroma cell produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 2
Dependent Claim
70 words
A quadroma cell, wherein said quadroma cell is the fusion product of a first hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen and a second hybridoma cell which produces an antibody having specific binding affinity for a second desired antigen, and wherein said quadroma cell produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 3
Dependent Claim
16 words
The quadroma cell of claim 1, wherein one of the two antigens is a tumor-associated antigen.
Claim 4
Dependent Claim
16 words
The quadroma cell to claim 1, wherein one of the two antigens is a cell-specific antigen.
Claim 5
Dependent Claim
16 words
The quadroma cell of claim 1, wherein one of the two antigens is a tissue-specific antigen.
Claim 6
Dependent Claim
19 words
The quadroma cell of claims 1, 2, 3 or 4, wherein one of the two antigens is an enzyme.
Claim 7
Dependent Claim
19 words
The quadroma cell of claims 1, 2, 3 or 4, wherein one of the two antigens is a hapten.
Claim 8
Dependent Claim
19 words
The quadroma cell of claims 1 or 2 wherein one of the two antigens is a Ricinus communis toxin.
Claim 9
Dependent Claim
18 words
The quadroma cell of claims 1 or 2, wherein one of the two antigens is specific for trinitrophenol.
Claim 10
Dependent Claim
11 words
The quadroma cell of claim 6, wherein the hapten is radioactively-labelled.
Claim 11
Dependent Claim
23 words
The quadroma cell of claim 1, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is a hapten.
Claim 12
Dependent Claim
23 words
The quadroma cell of claim 1, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is horseradish peroxidase.
Claim 13
Dependent Claim
16 words
The quadroma cell of claims 1 or 2, wherein one of the two antigens is fluorescein.
Claim 14
Dependent Claim
13 words
The quadroma cell of claim 1, wherein said antibody is an IgM molecule.
Claim 15
Dependent Claim
13 words
The quadroma cell of claim 1, wherein said antibody is an IgG molecule.
Claim 16
Dependent Claim
67 words
A trioma cell, wherein said trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen and a lymphocyte which produces an antibody having specific binding affinity to a second desired antigen, and wherein said trioma cell produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 17
Dependent Claim
67 words
A trioma cell, wherein said trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen and a lymphocyte which produces an antibody having specific binding affinity to a second desired antigen, and wherein said trioma cell produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 18
Dependent Claim
16 words
The trioma cell of claim 15, wherein one of the two antigens is a tumor-associated antigen.
Claim 19
Dependent Claim
15 words
The trioma cell of claim 15, wherein one of two antibodies is a cell-specific antigen.
Claim 20
Dependent Claim
16 words
The trioma cell of claim 15, wherein one of the two antigens is a tissue-specific antigen.
Claim 21
Dependent Claim
19 words
The trioma cell of claims 15, 16, 17 or 18, wherein one of the two antigens is an enzyme.
Claim 22
Dependent Claim
19 words
The trioma cell of claims 15, 16, 17 or 18, wherein one of the two antigens is a hapten.
Claim 23
Dependent Claim
18 words
The trioma cell of claims 15 or 16, wherein one of the two antigens is Ricinus communis toxin.
Claim 24
Dependent Claim
18 words
The trioma cell of claims 15 or 16, wherein one of the two antigens is specific for trinitrophenol.
Claim 25
Dependent Claim
11 words
The trioma cell of claim 20, wherein the hapten is radioactively-labelled.
Claim 26
Dependent Claim
23 words
The trioma cell of claim 15, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is a hapten.
Claim 27
Dependent Claim
23 words
The trioma cell of claim 15, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is horseradish peroxidase.
Claim 28
Dependent Claim
14 words
The trioma cell of claim 15, wherein one of the two antigens is fluorescein.
Claim 29
Dependent Claim
13 words
The trioma cell of claim 15, wherein said antibody is an IgM molecule.
Claim 30
Dependent Claim
13 words
The trioma cell of claim 15, wherein said antibody is an IgG molecule.
Claim 31
Independent Claim
70 words
A method of producing a quadroma cell comprising: (A) fusing a first hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen, to a second hybridoma cell which produces an antibody having specific binding affinity to a second desired antigen, and (B) selecting a quadroma cell which produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 32
Independent Claim
70 words
A method of producing a quadroma cell comprising: (A) fusing a first hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen, to a second hybridoma cell which produces an antibody having specific binding affinity to a second desired antigen, and (B) selecting a quadroma cell which produces a recombinant monoclonal antibody having specific binding affinity for both said first and said second desired antigens.
Claim 33
Dependent Claim
15 words
The method of claim 29, wherein one of the two antigens is a tumor-associated antigen.
Claim 34
Dependent Claim
15 words
The method of claim 29, wherein one of the two antigens is a cell-specific antigen.
Claim 35
Dependent Claim
15 words
The method of claim 29, wherein one of the two antigens is a tissue-specific antigen.
Claim 36
Independent Claim
18 words
The method of claims 29, 30, 31 or 32, wherein one of the two antigens is an enzyme.
Claim 37
Independent Claim
18 words
The method of claims 29, 30, 31 or 32, wherein one of the two antigens is a hapten.
Claim 38
Independent Claim
17 words
The method of claims 29 or 30, wherein one of the two antigens is Ricinus communis toxin.
Claim 39
Independent Claim
17 words
The method of claims 29 or 30, wherein one of the two antigens is specific for trinitrophenol.
Claim 40
Dependent Claim
10 words
The method of claim 34, wherein the hapten is radioactively-labelled.
Claim 41
Dependent Claim
22 words
The method of claim 29, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is a hapten.
Claim 42
Dependent Claim
22 words
The method of claim 29, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is horseradish peroxidase.
Claim 43
Independent Claim
15 words
The method of claims 29 or 30, wherein one of the two antigens is fluorescein.
Claim 44
Dependent Claim
14 words
The method of claim 29, wherein said recombinant monoclonal antibody is an IgM molecule.
Claim 45
Dependent Claim
14 words
The method of claim 29, wherein said recombinant monoclonal antibody is an IgG molecule.
Claim 46
Independent Claim
66 words
A method of producing a trioma cell comprising: (A) fusing a hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen, to a lymphocyte which produces an antibody having specific binding affinity to a second desired antigen, and (B) selecting a trioma cell which produces a recombinant monoclonal antibody having specific binding affinity for both said first and second desired antigens.
Claim 47
Independent Claim
66 words
A method of producing a trioma cell comprising: (A) fusing a hybridoma cell which produces an antibody having specific binding affinity to a first desired antigen, to a lymphocyte which produces an antibody having specific binding affinity to a second desired antigen, and (B) selecting a trioma cell which produces a recombinant monoclonal antibody having specific binding affinity for both said first and second desired antigens.
Claim 48
Dependent Claim
15 words
The method of claim 43, wherein one of the two antigens is a tumor-associated antigen.
Claim 49
Dependent Claim
15 words
The method of claim 43, wherein one of the two antigens is a cell-specific antigen.
Claim 50
Dependent Claim
15 words
The method of claim 43, wherein one of the two antigens is a tissue-specific antigen.
Claim 51
Independent Claim
18 words
The method of claims 43, 44, 45 or 46, wherein one of the two antigens is an enzyme.
Claim 52
Independent Claim
18 words
The method of claims 43, 44, 45 or 46, wherein one of the two antigens is a hapten.
Claim 53
Independent Claim
17 words
The method of claims 43 or 44, wherein one of the two antigens is Ricinus communis toxin.
Claim 54
Independent Claim
17 words
The method of claims 43 or 44, wherein one of the two antigens is specific for trinitrophenol.
Claim 55
Dependent Claim
10 words
The method of claim 48, wherein the hapten is radioactively-labelled.
Claim 56
Dependent Claim
22 words
The method of claim 43, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is a hapten.
Claim 57
Dependent Claim
22 words
The method of claim 43, wherein one of the two antigens is human chorionic gonadotropin and the other antigen is horseradish peroxidase.
Claim 58
Dependent Claim
13 words
The method of claim 43, wherein one of the two antigens is fluorescein.
Claim 59
Dependent Claim
14 words
The method of claim 43, wherein said recombinant monoclonal antibody is an IgM molecule.
Claim 60
Dependent Claim
14 words
The method of claim 43, wherein said recombinant monoclonal antibody is an IgG molecule.
References Cited (Backward Citations)
US4196265A
Cited
US4172124A
Cited
US4350683A
Cited
EP0068763A2
Cited
US4474893A
Cited
WO1983000525A1
Cited
US4444878A
Cited
US4529694A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-12-21 | 1991-06-22 | 1991-12-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-12-21 | 1995-06-22 | 1995-12-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-12-21 | 1999-06-22 | 1999-12-22 | $7700.00 | Window Closed / Lapsed |